Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Home Depot Inc (HD) Price & Performance

Cassava Sciences IncTrade
Home Depot IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Home Depot Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Home Depot Inc trades at $354.5 (market cap $349.77B). The key difference: Home Depot Inc is far larger — about 7325× Cassava Sciences Inc's market cap, and Home Depot Inc pays a 2.66% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAHD
Market Cap
$47.75M$349.77B
Sector
HealthConsumer Cyclical
52-Week High
$4.64$423.42
52-Week Low
$0.87$297.51
Enterprise Value
-$34.93M$411.32B
Dividend Yield
2.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Home Depot Inc

Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in 2025 revenue with solid profitability metrics including 8.41% net income margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations set at $4.73 EPS. The stock faces headwinds from weakening big-ticket demand and rising mortgage rates, but maintains strong analyst support with 59% buy ratings.

Home Depot presents a compelling long-term investment case with stable fundamentals and professional segment growth potential, though near-term challenges include housing market sensitivity and margin pressure. The consensus price target of $368.75 suggests 5.1% upside potential from current levels, supported by strong cash flow generation and dividend payments. Key risks include consumer spending volatility and competitive pressures in the home improvement sector.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Home Depot Inc

Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.

Read more on HD